Current management strategies for hepatocellular carcinoma

Minerva Gastroenterologica e Dietologica

Volumn 59, Issue 2, 2013, Pages 143-159

  Czaja, A J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Carcinoma, hepatocellular; Diagnosis.; Immunologic surveillance

Indexed keywords

SORAFENIB;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CHEMOEMBOLIZATION; ECHOGRAPHY; EVIDENCE BASED PRACTICE; HUMAN; HYPERBILIRUBINEMIA; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT DECISION MAKING; PATIENT REFERRAL; PORTAL HYPERTENSION; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT PLANNING; TUMOR INVASION;

ALGORITHMS; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84884697748     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012 [Epub ahead of print].
3. Abou-Alfa GK, Huitzil-Melendez FD, O'Reilly EM, Saltz LB. Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res 2008;2:64-70.
4. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002,963:13-20. (Pubitemid 34721691)
5. El-Serag HB. Hepatocellular carcinoma. New Engl J Med 2011;365:1118-27.
6. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21.
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
8. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127:S87-96. (Pubitemid 39423374)
9. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9. (Pubitemid 26079803)
10. Manghisi G, Elba S, Mossa A, Giorgio A, Aloisio V, Perrotta A et al. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-5.
11. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
12. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellular. J Hepatol 1999;31:133-41. (Pubitemid 29287619)
13. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403. (Pubitemid 32496976)
14. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-96. (Pubitemid 47561609)
15. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
16. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-64.
17. Burak KW, Kneteman NM. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol 2010;24:643-50.
18. Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int 2012;32:1053-63.
19. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13.e11-22.
20. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
21. Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19.
22. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.
23. Nishida N, Goel A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 2011;12:130-7.
24. Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol 2010;3:55-66.
25. Mathur AK, Schaubel DE, Gong Q, Guidinger MK, Merion RM. Racial and ethnic disparities in access to liver transplantation. Liver Transpl 2010;16:1033-40.
26. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132-41.
27. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011;154:85-93.
28. Czaja AJ. Hepatocellular cancer and other malignancies in autoimmune hepatitis. Dig Dis Sci 2013 [Epub ahead of print].
29. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008;103:1944-51.
30. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.
31. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 2008;48:863-70.
32. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-72.
33. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype lb as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009;50:1142-54.
34. Montella M, Polesel J, La Vecchia C, Dal Maso L, Crispo A, Crovatto M et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007;120:1555-9. (Pubitemid 46355393)
35. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013;144:323-32.
36. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008;48:200-7.
37. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008;299:53-60.
38. Clifford RJ, Zhang J, Meerzaman DM, Lyu MS, Hu Y, Cultraro CM et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology 2010;52:2034-43.
39. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008;47:82-9. (Pubitemid 351171044)
40. Sandhu L, Sandroussi C, Guba M, Selzner M, Ghanekar A, Cattral MS et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transplant 2012;18:315-22.
41. Ho CM, Lee PH, Chen CL, Ho MC, Wu YM, Hu RH. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. Ann Surg Oncol 2012;19:826-33.
42. Sherman M, Bruix J, Porayko M, Tran T. Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012;56:793-6.
43. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl l):S20-37.
44. Yang JD, Kim WR. Surveillance for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2012;10:16-21.
45. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Int Med 2012;156:387-9.
46. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003;10:204-9. (Pubitemid 38091209)
47. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
48. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802-29.
49. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M et al. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010;19:311-7.
50. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.
51. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350-91.
52. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-33.
53. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-6. (Pubitemid 30430422)
54. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-41. (Pubitemid 37500438)
55. Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001;96:1160-3. (Pubitemid 32319154)
56. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010;53:291-7.
57. Sherman M. Serological surveillance for hepatocellular carcinoma: time to quit. J Hepatol 2010;52:614-5.
58. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9. (Pubitemid 32141852)
59. Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001;20:99-104.
60. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
61. Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009;3:544-50.
62. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104. (Pubitemid 351171046)
63. Yu NC, Chaudhari V, Raman SS, Lassman C, Tong MJ, Busuttil RW et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011;9:161-7.
64. Nakashima Y, Nakashima O, Hsia CC, Kojiro M, Tabor E. Vascularization of small hepatocellular carcinomas: correlation with differentiation. Liver 1999;19:12-8. (Pubitemid 29034105)
65. Qayyum A, Graser A, Westphalen A, Merriman RB, Ferrell LD, Yeh BM et al. CT of benign hypervascular liver nodules in autoimmune hepatitis. AJR 2004;183:1573-6. (Pubitemid 44210522)
66. Roskams T. Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. Clin Liver Dis 2011;15:245-59.
67. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008;57:1592-6.
68. Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. (Pubitemid 47527466)
69. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-64.
70. Coakley FV, Schwartz LH. Imaging of hepatocellular carcinoma: a practical approach. Semin Oncol 2001;28:460-73. (Pubitemid 32959593)
71. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010;30:17-25.
72. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97. (Pubitemid 36799110)
73. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007;45:725-34. (Pubitemid 46450624)
74. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009;137:850-5.
75. Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 2013;20:325-39.
76. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
77. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-40.
78. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707-16. (Pubitemid 40462931)
79. Cilio U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723-31.
80. Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D'Onofrio M et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008;103:597-604. (Pubitemid 351405970)
81. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;44:239-45.
82. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S et al. Predictive factors for post-operative recurrence of hepatocellular carcinoma. Gastroenterology 1994;106:1618-24. (Pubitemid 24163135)
83. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-9.
84. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353-7.
85. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42. (Pubitemid 36152543)
86. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9. (Pubitemid 34607087)
87. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-9. (Pubitemid 44142456)
88. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-81. (Pubitemid 46201723)
89. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012;56:1330-5.
90. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-7. (Pubitemid 29023987)
91. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-83.
92. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
93. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17(Suppl 2):S44-57.
94. Chang CH, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Long-term results of hepatic resection for hepatocellular carcinoma originating from the non-cirrhotic liver. Arch Surg 2004;139:320-5.
95. Mergental H, Porte RJ. Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Transpl Int 2010;23:662-7.
96. Sawada T, Kubota K. Liver transplantation for hepatocellular carcinoma. Dig Surg 2007;24:126-30. (Pubitemid 46788279)
97. Vakili K, Pomposelii JJ, Cheah YL, Akoad M, Lewis WD, Khettry U et al. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl 2009;15:1861-6.
98. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cesran M, Ercolani G et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008;8:2547-57.
99. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ, 3rd, Bass NM, Feng S et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-27.
100. Lencioni R, Cioni D, Delia Pina C, Crocetti L, Bartolozzi C. Imaging diagnosis. Semin Liver Dis 2005;25:162-70. (Pubitemid 40781069)